Wednesday, February 10, 2010, 5:54am EST - Canadian Markets open in 3 hours and 36 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

CEL-SCI Corp. (CVM)

 On Feb 9: 0.65 USD   0.00 (0.00%)  
MORE ON CVM
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
CEL-SCI CORP (AMEX:CVM) Delayed quote dataEdit
Last Trade: 0.65 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 0.65
Open: N/A
Bid: N/A
Ask: N/A
1y Target Est: 1.00
Day's Range: N/A - N/A
52wk Range: 0.14 - 2.10
Volume: 0
Avg Vol (3m): 3,290,760
Market Cap: 132.25M
P/E (ttm): N/A
EPS (ttm): -0.099
Div & Yield: N/A (N/A%)
CEL-SCI Corp. (CVM)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add CVM to Portfolio   Download Data

HEADLINES
• CEL SCI CORP Financials
EDGAR Online Financials (Sat, Feb 6)
• CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference
PRNewswire (Wed, Feb 3)
• CEL SCI CORP Files SEC form 10-Q/A, Quarterly Report
EDGAR Online (Mon, Feb 1)
• CEL SCI CORP Files SEC form 10-Q/A, Quarterly Report
EDGAR Online (Fri, Jan 29)
• Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corp.
Marketwire (Mon, Jan 25)
• CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
PRNewswire (Fri, Jan 15)
• Cel-Sci reports more cash, higher year-end losses
at bizjournals.com (Wed, Jan 13)
• CEL SCI CORP Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or Interim Review
EDGAR Online (Wed, Jan 13)
• CEL-SCI Corporation Announces 2009 Financial Results
PRNewswire (Wed, Jan 13)
• Cel-Sci manufacturing facility gets go ahead
at bizjournals.com (Mon, Jan 11)
More Headlines for CVM...
ANALYST
EPS Est (next year) (Sep-08) : N/A
EPS Est (in 2 years) (Sep-09) : N/A
Avg Rec (current)*: N/A
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. The company's lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices